scholarly journals Antimicrobial use Guidelines for Treatment of Respiratory Tract Disease in Dogs and Cats: Antimicrobial Guidelines Working Group of the International Society for Companion Animal Infectious Diseases

2017 ◽  
Vol 31 (2) ◽  
pp. 279-294 ◽  
Author(s):  
M.R. Lappin ◽  
J. Blondeau ◽  
D. Boothe ◽  
E.B. Breitschwerdt ◽  
L. Guardabassi ◽  
...  
Keyword(s):  
Infectious Diseases ◽  
Respiratory Tract ◽  
International Society ◽  
Working Group ◽  
Companion Animal ◽  
Antimicrobial Use ◽  
Respiratory Tract Disease ◽  
Tract Disease

scholarly journals Antimicrobial Use Guidelines for Treatment of Urinary Tract Disease in Dogs and Cats: Antimicrobial Guidelines Working Group of the International Society for Companion Animal Infectious Diseases

2011 ◽  
Vol 2011 ◽  
pp. 1-9 ◽  
Author(s):  
J. Scott Weese ◽  
Joseph M. Blondeau ◽  
Dawn Boothe ◽  
Edward B. Breitschwerdt ◽  
Luca Guardabassi ◽  
...  
Keyword(s):  
Urinary Tract ◽  
Infectious Diseases ◽  
Urinary Tract Infections ◽  
International Society ◽  
Working Group ◽  
Companion Animal ◽  
Comprehensive Treatment ◽  
Diagnosis And Management ◽  
Tract Disease ◽  
Tract Infections

Urinary tract disease is a common reason for use (and likely misuse, improper use, and overuse) of antimicrobials in dogs and cats. There is a lack of comprehensive treatment guidelines such as those that are available for human medicine. Accordingly, guidelines for diagnosis and management of urinary tract infections were created by a Working Group of the International Society for Companion Animal Infectious Diseases. While objective data are currently limited, these guidelines provide information to assist in the diagnosis and management of upper and lower urinary tract infections in dogs and cats.

scholarly journals Guidelines for the diagnosis and antimicrobial therapy of canine superficial bacterial folliculitis (Antimicrobial Guidelines Working Group of the International Society for Companion Animal Infectious Diseases)

2014 ◽  
Vol 25 (3) ◽  
pp. 163-e43 ◽  
Author(s):  
Andrew Hillier ◽  
David H. Lloyd ◽  
J. Scott Weese ◽  
Joseph M. Blondeau ◽  
Dawn Boothe ◽  
...  
Keyword(s):  
Infectious Diseases ◽  
International Society ◽  
Antimicrobial Therapy ◽  
Working Group ◽  
Companion Animal

scholarly journals LB14. Efficacy and Immunogenicity of an Ad26.RSV.preF-based Vaccine in the Prevention of RT-PCR-confirmed RSV-mediated Lower Respiratory Tract Disease in Adults Aged ≥65 Years: A Randomized, Placebo-controlled, Phase 2b Study

2021 ◽  
Vol 8 (Supplement_1) ◽  
pp. S812-S812
Author(s):  
Ann R Falsey ◽  
Kristi Williams ◽  
Efi Gymnopoulou ◽  
Stephan A Bart ◽  
John E Ervin ◽  
...  
Keyword(s):  
Infectious Diseases ◽  
Respiratory Tract ◽  
Respiratory Infection ◽  
Lower Respiratory Tract ◽  
Respiratory Tract Disease ◽  
Rt Pcr ◽  
Research Support ◽  
Lower Respiratory Tract Disease ◽  
First Occurrence ◽  
Tract Disease

Abstract Background Respiratory syncytial virus (RSV) can cause serious lower respiratory tract disease (LRTD) in older adults. Despite a high burden of disease, there is currently no licensed vaccine for RSV. Here, we report the primary efficacy and immunogenicity results from a Phase 2b proof-of-concept trial of an Ad26.RSV.preF-based vaccine for the prevention of RSV-mediated LRTD in adults aged ≥65 years. Methods CYPRESS (NCT03982199) is a randomized, double-blind, placebo-controlled Phase 2b trial. Adults ≥65 years of age were randomized 1:1 prior to the RSV season to receive an Ad26.RSV.preF-based vaccine or placebo. Symptoms of acute respiratory infection (ARI) were collected through an RSV-specific patient-reported Respiratory Infection Intensity and Impact Questionnaire (RiiQ) and/or by a clinician assessment until the end of the RSV season. The primary endpoint was the first occurrence of RT-PCR-confirmed RSV-mediated LRTD according to any of 3 case definitions: (1) ≥3 symptoms of lower respiratory tract infection (LRTI), (2) ≥2 symptoms of LRTI, or (3) ≥2 symptoms of LRTI or ≥1 symptom of LRTI with ≥1 systemic symptom. The secondary endpoint was the first occurrence of any RT-PCR-confirmed RSV-mediated ARI. Immunogenicity assessments were performed in a subset of approximately 200 participants. Results A total of 5782 participants (2891 in each study arm) received study treatment (92.5% white, 57.7% female, median age 71 years). Vaccine efficacy was 80% (94.2% CI, 52.2–92.9%), 75% (50.1–88.5%), and 69.8% (43.7–84.7%) for case definition 1, 2, and 3, respectively (all P values < 0.001). Efficacy for any RSV-mediated ARI was 69.8% (95% CI, 42.7–85.1%). In the vaccine arm of the immunogenicity subset, geometric mean fold increase in antibody titers 14 days after vaccination was 13.5 for RSV neutralizing antibodies and 8.6 for RSV prefusion F-specific binding antibodies. Median frequency of RSV-F-specific INFγ T-cells increased from 34 to 444 SFC/106 PBMC 14 days after vaccination in the vaccine arm; no relevant changes were observed in the placebo arm. Conclusion In CYPRESS, the Ad26.RSV.preF-based vaccine was highly effective against RSV-mediated LRTD through the first RSV season and elicited robust humoral and cellular immune responses in adults aged ≥65 years. Disclosures Ann R. Falsey, MD, AstraZeneca (Individual(s) Involved: Self): Grant/Research Support; BioFire Diagnostics (Individual(s) Involved: Self): Grant/Research Support; Janssen (Individual(s) Involved: Self): Grant/Research Support; Merck, Sharpe and Dohme (Individual(s) Involved: Self): Grant/Research Support; Novavax (Individual(s) Involved: Self): Other Financial or Material Support, Paid DSMB member; Pfizer (Individual(s) Involved: Self): Grant/Research Support Kristi Williams, PhD, Janssen R&D US (Employee) Efi Gymnopoulou, MSc, Janssen Infectious Diseases BV (Employee) Arangassery Rosemary Bastian, PhD, Janssen Vaccines & Prevention BV (Employee) Joris Menten, n/a, Janssen Infectious Diseases BV (Employee) Els De Paepe, MSc, Janssen Infectious Diseases BV (Employee) Hilde de Boer, MSc, Janssen-Cilag (Employee) Sjoukje Vandenberghe, n/a, Janssen Infectious Diseases BV (Employee) Eric Chan, PhD, Janssen Global Services, LLC (Employee) Jerald Sadoff, MD, Johnson & Johnson (Employee, Shareholder) Macaya Douoguih, MD, MPH, Janssen (Employee) Benoit Callendret, PhD, Janssen Vaccines & Prevention BV (Employee) Christy Comeaux, MD, Janssen Vaccines & Prevention BV (Employee) Esther Heijnen, MD, Janssen Vaccines & Prevention BV (Employee)

scholarly journals Post-slaughter changes in rabbit carcasses in Poland between 2010 and 2018

2019 ◽  
Vol 75 (10) ◽  
pp. 6294-2019
Author(s):  
ŁUKASZ DROZD ◽  
WALDEMAR PASZKIEWICZ ◽  
RENATA PYZ-ŁUKASIK ◽  
MONIKA ZIOMEK ◽  
KRZYSZTOF SZKUCIK
Keyword(s):  
Infectious Diseases ◽  
Respiratory Tract ◽  
Fold Increase ◽  
Parasitic Diseases ◽  
Upper Respiratory Tract ◽  
Pathological Changes ◽  
Respiratory Tract Disease ◽  
Internal Organs ◽  
Upper Respiratory ◽  
Tract Disease

The aim of the study was to analyze the results of sanitary and veterinary examinations of rabbits carried out by the Veterinary Inspectorate in slaughterhouses in Poland in 2010-2018. In this period, 8,980,660 rabbits were examined. Lesions and quality deviations were found in 42,779 carcasses, i.e. 0.48% of all carcasses examined. The most frequent causes of the rejection of the carcasses and internal organs of the rabbits examined were sepsis and pyaemia (36,369 cases), followed by excessive emaciation (1,686 cases), upper respiratory tract disease (1,655 cases), other causes not specified by name (1,438 cases), and coccidiosis (1,318 cases). Abnormal exsanguination (303), parasitic diseases other than coccidiosis (67), infectious diseases (14), and leukemia (2) were much less often the cause of rejection. During the period analyzed, there was a decrease in the number of cases of coccidiosis (except in 2017) and other parasitic diseases, but there was a several-fold increase in the occurrence of sepsis and pyaemia (in the years 2015-2018). Compared with the results of veterinary and sanitary examinations of rabbits in 2000-2010, there was an increase in the number of rabbits slaughtered and a reduction in the percentage of carcasses with pathological changes and carcasses deemed unfit for consumption. In the years 2010-2018, there was also an increase in the number of cases of sepsis and pyaemia and a significant decrease in the percentage of parasitic diseases (mainly coccidiosis).

Feline chaphamaparvovirus (FeChPV) in cats with enteritis and upper respiratory tract disease (URTD)

2021 ◽  
Author(s):  
Federica Di Profio ◽  
Vittorio Sarchese ◽  
Andrea Palombieri ◽  
Paola Fruci ◽  
Ivano Massirio ◽  
...  
Keyword(s):  
Respiratory Tract ◽  
Upper Respiratory Tract ◽  
Respiratory Tract Disease ◽  
Upper Respiratory ◽  
Upper Respiratory Tract Disease ◽  
Tract Disease

Occurrence of infectious upper respiratory tract disease and response to vaccination in horses on six sentinel premises in northern Colorado

2010 ◽  
Vol 35 (1) ◽  
pp. 72-77 ◽  
Author(s):  
E. L. MUMFORD ◽  
J. L. TRAUB-DARGATZ ◽  
J. CARMAN ◽  
R. J. CALLAN ◽  
J. K. COLLINS ◽  
...  
Keyword(s):  
Respiratory Tract ◽  
Upper Respiratory Tract ◽  
Respiratory Tract Disease ◽  
Northern Colorado ◽  
Upper Respiratory ◽  
Upper Respiratory Tract Disease ◽  
Tract Disease

IgG Subclass Deficiency and Recurrent Respiratory Tract Disease in Childhood

1988 ◽  
Vol 2 (4) ◽  
pp. 269-278 ◽  
Author(s):  
JERALD M. DUNCAN ◽  
HENRY G. HERROD ◽  
LLOYD V. CRAWFORD
Keyword(s):  
Respiratory Tract ◽  
Igg Subclass ◽  
Respiratory Tract Disease ◽  
Igg Subclass Deficiency ◽  
Subclass Deficiency ◽  
Tract Disease

scholarly journals Construction and Characterization of a Recombinant Human Respiratory Syncytial Virus Encoding Enhanced Green Fluorescence Protein for Antiviral Drug Screening Assay

2018 ◽  
Vol 2018 ◽  
pp. 1-8 ◽  
Author(s):  
Min Xu ◽  
Yue-Ying Jiao ◽  
Yuan-Hui Fu ◽  
Nan Jiang ◽  
Yuan-Bo Zheng ◽  
...  
Keyword(s):  
Respiratory Syncytial Virus ◽  
Respiratory Tract ◽  
Drug Screening ◽  
Green Fluorescence Protein ◽  
Respiratory Tract Disease ◽  
Green Fluorescence ◽  
Enhanced Green Fluorescence Protein ◽  
Fluorescence Protein ◽  
Syncytial Virus ◽  
Tract Disease

Human respiratory syncytial virus (RSV) is the single most important cause of lower respiratory tract disease in infants and young children and a major viral agent responsible for respiratory tract disease in immunosuppressed individuals and the elderly, but no vaccines and antiviral drugs are available. Herein the recombinant RSV (rRSV) encoding enhanced green fluorescence protein (EGFP, rRSV-EGFP) was constructed and the potential for screening anti-RSV drugs was investigated. The recombinant plasmid of pBRATm-rRSV-EGFP, containing T7 transcription cassette composed of T7 promoter, RSV antigenomic cDNA with EGFP gene, HDV ribozyme (δ), and T7 terminator in the order of 5′ to 3′, was constructed and cotransfected into BHK/T7-9 cells together with helper plasmids encoding N, P, L, and M2-1 gene, respectively. The rescued rRSV-EGFP was confirmed by increasing expression of EGFP over blind passages and by RT-PCR. rRSV-EGFP was comparable to the other two recombinant RSVs encoding red fluorescent protein (RFP, rRSV-RFP) or luciferase (Luc, rRSV-Luc) in the growth kinetic, and there was a difference in sensitivity between them for screening anti-RSV agents based on infection of HEp-2 cells. The EGFP-encoding rRSV has been constructed and rescued successfully and has the potential for high-throughput anti-RSV drug screening in vitro.

Clinical Characteristics of the Afebrile Pneumonia Associated With Chlamydia trachomatis Infection in Infants Less Than 6 Months of Age

PEDIATRICS ◽  
1979 ◽  
Vol 63 (2) ◽  
pp. 192-197
Author(s):  
Margaret A. Tipple ◽  
Marc O. Beem ◽  
Evelyn M. Saxon
Keyword(s):  
Chlamydia Trachomatis ◽  
Respiratory Tract ◽  
Lower Respiratory Tract ◽  
Clinical Characteristics ◽  
Respiratory Tract Disease ◽  
Chlamydia Trachomatis Infection ◽  
Lower Respiratory Tract Disease ◽  
Tract Disease ◽  
Blood Eosinophils ◽  
Respiratory Tract Colonization

Respiratory tract colonization with Chlamydia trachomatis commonly occurs in natally acquired chlamydial infection and is sometimes associated with a chronic, afebrile pneumonia that has relatively distinctive clinical characteristics. To further define the frequency and clinical characteristics of lower respiratory tract disease associated with C trachomatis, we grouped 56 infants aged less than 6 months with afebrile pneumonia according to nasopharyngeal shedding of Chlamydia and viruses and compared their illnesses. Forty-one (73%) were positive for C trachomatis (23 had C trachomatis only, while 18 had C trachomatis plus a virus [cytomegalovirus, respiratory synctial virus, adenovirus, rhinovirus, or enterovirus]), and 15 were C trachomatis negative (nine had a virus only, and six had neither C trachomatis nor virus). The 41 infants with C trachomatis alone or C trachomatis plus a virus were similar clinically and differed significantly from other infants in several ways: (1) onset of symptoms before 8 weeks of age; (2) gradually worsening symptoms; (3) presentation for care at 4 to 11 weeks of age; (4) presence of conjunctivitis and ear abnormalities; (5) chest roentgenograms showing bilateral, symmetrical, interstitial infiltrates and hyperexpansion; (6) peripheral blood eosinophils ≥300/cu mm; and (7) elevated values for serum immunoglobulins M, G, and A.

Sign in / Sign up

Export Citation Format

Share Document